Humankind Investments LLC Has $3.12 Million Holdings in Eli Lilly and Company $LLY

Key Points

• Humankind Investments LLC reduced its holdings in Eli Lilly and Company by 13.5%, now owning 3,780 shares valued at approximately $3.12 million.
• Insider directors Jamere Jackson and Gabrielle Sulzberger increased their ownership in Eli Lilly by purchasing 200 and 117 shares, respectively, signaling confidence in the company's prospects.
• Analysts have resulted in a mixed outlook for Eli Lilly, with price targets ranging from $895 to $1,050, and an average target price of $950.17.

Humankind Investments LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 13.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,780 shares of the company's stock after selling 588 shares during the quarter. Eli Lilly and Company accounts for approximately 0.8% of Humankind Investments LLC's holdings, making the stock its 17th largest holding. Humankind Investments LLC's holdings in Eli Lilly and Company were worth $3,122,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. HMS Capital Management LLC acquired a new stake in Eli Lilly and Company during the 1st quarter worth $1,431,000. Vertex Planning Partners LLC raised its stake in shares of Eli Lilly and Company by 5.9% in the 1st quarter. Vertex Planning Partners LLC now owns 632 shares of the company's stock valued at $522,000 after purchasing an additional 35 shares during the period. EntryPoint Capital LLC acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at about $330,000. Heritage Financial Services LLC raised its stake in shares of Eli Lilly and Company by 3.6% in the 1st quarter. Heritage Financial Services LLC now owns 1,886 shares of the company's stock valued at $1,558,000 after purchasing an additional 66 shares during the period. Finally, Groupama Asset Managment raised its stake in shares of Eli Lilly and Company by 10.2% in the 1st quarter. Groupama Asset Managment now owns 101,222 shares of the company's stock valued at $83,256,000 after purchasing an additional 9,384 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Buying and Selling

In other Eli Lilly and Company news, Director Jamere Jackson purchased 200 shares of the company's stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Gabrielle Sulzberger acquired 117 shares of the stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock valued at $2,894,841 in the last quarter. Corporate insiders own 0.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on LLY. UBS Group dropped their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average target price of $950.17.

Eli Lilly and Company Trading Up 0.8%

Eli Lilly and Company stock opened at $703.5670 on Wednesday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $972.53. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market capitalization of $665.90 billion, a P/E ratio of 45.98, a PEG ratio of 0.97 and a beta of 0.44. The stock has a 50-day simple moving average of $760.97 and a 200 day simple moving average of $793.02.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the previous year, the company posted $3.92 earnings per share. The business's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is presently 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.